Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 565 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cequa Clear all

Conditions: Breast Cancer
Interventions: filgrastim, monoclonal antibody m170, cyclosporine, paclitaxel, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody m170; Biological · Drug · Procedure + 1 more
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Leukemia
Interventions: asparaginase, cyclophosphamide, cyclosporine, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, methylprednisolone, pegaspargase, thioguanine, vincristine sulfate, allogeneic bone marrow transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 1 Year
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 47
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 38 more

Conditions: Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, T-Cell Non-Hodgkin Lymphoma
Interventions: Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant, Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells, Total Nodal Irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: Robert Lowsky; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Dry Eye
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Dry Eye
Interventions: NOVA22007 ''Cyclosporine'', vehicle/placebo; Drug
Lead sponsor: Santen SAS; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Lewiston, Maine

Conditions: Type 1 Diabetes Mellitus
Interventions: cyclosporin and methotrexate; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 8 Years to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 1994
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Aplastic Anemia
Interventions: Romiplostim, Immunosuppressive therapy (IST); Drug
Lead sponsor: Anjali Sharathkumar; Other
Eligibility: 2 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure
Interventions: calcineurin inhibitor-based immunosuppression, liver transplant, corticosteroids, immunosuppression withdrawal; Drug · Procedure · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 8
States / cities: San Francisco, California • Denver, Colorado • Chicago, Illinois + 5 more

Conditions: Acute Myeloid Leukemia
Interventions: peg-IFN-α, Hematopoietic Cell Transplant (HCT), Tacrolimus, Methotrexate; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Aplastic Anemia
Interventions: cyclophosphamide, anti-thymocyte globulin, cyclosporine, allogeneic bone marrow transplantation, methotrexate, DNA analysis, flow cytometry, polymorphism analysis, laboratory biomarker analysis; Drug · Biological · Procedure + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 3
States / cities: Salt Lake City, Utah • Seattle, Washington • Milwaukee, Wisconsin

Conditions: Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma
Interventions: rituximab, ibritumomab tiuxetan, anti-thymocyte globulin, total nodal irradiation, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation, cyclosporine, mycophenolate mofetil; Biological · Radiation · Procedure + 1 more
Lead sponsor: Joseph Tuscano; Other
Eligibility: 19 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Transplantation, Renal, Immunosuppression
Interventions: Mycophenolate Mofetil; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Graft Versus Host Disease, Leukemia, Lymphoma
Interventions: anti-thymocyte globulin, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2000
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Kidney Graft Dysfunction
Interventions: Cyclosporins/Tacrolimus, Sirolimus; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 46
States / cities: Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 43 more

Conditions: Dry Eye
Interventions: Systane, Optive, Restasis; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Slingerlands, New York

Conditions: Sarcoma
Interventions: F-18 Fluorodeoxyglucose, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, melphalan, prednisone, sirolimus, tacrolimus, vincristine sulfate, peripheral blood stem cell transplantation, Filgrastim, Peripheral Blood Stem Cell donation; Drug · Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 5 Years to 35 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Renal Transplant
Interventions: Calcineurin inhibitor withdrawal; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Colorectal Cancer
Interventions: cyclosporine, CPT-11; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 10
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more

Conditions: Lymphoma
Interventions: carmustine, cyclophosphamide, etoposide, peripheral blood stem cell transplantation, irradiation therapy, G-CSF, Cytarabine; Drug · Procedure · Radiation + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 75 Years
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia, Multiple Myeloma
Interventions: Rituximab, Cyclosporine, Allogenic stem cell transplant (ASCT), Conditioning Chemotherapy, TMS, FLAG, EPOCH-F, Alemtuzumab; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 74 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiomyopathy, Hypertrophic, Heart Hypertrophy
Interventions: Cyclosporine A; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Michael Mauer, MD; Individual
Eligibility: 18 Years to 60 Years
Enrollment: 655 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1981 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Graft Rejection
Interventions: everolimus; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 6
States / cities: Los Angeles, California • Minneapolis, Minnesota • New York, New York + 3 more

Search by objective public record fields.

Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

Tear Dynamics After Restasis Treatment in Dry Eye Patients

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

Low Dose Cyclosporin and Methotrexate Therapy in Diabetes

UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

MPA PK Monitoring Strategy With MMF/FK Based Immunosuppression

Bone Marrow Transplantation in Treating Patients With Leukemia

Kidney Allograft Dysfunction Without Reversible Causes

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation

Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)

Studies of Organ Transplantation in Animals and Man

Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy